News

News

Ropeginterferon alfa-2b-njft Approved for Polycythemia Vera

The U.S. Food and Drug Administration (FDA) has approved ropeginterferon alfa-2b-njft for the treatment of adult patients with polycythemia vera (PV). This decision is based...

Are Hospital Leaders Doing Enough to Address Supply Chain Issues?

A poll by consulting firm Sage Growth Partners on behalf of inventory management platform Syft found that among 100 organizations, 93% have taken action...

EZM0414 Granted Fast Track Designation for DLBCL

The U.S. Food and Drug Administration (FDA) has granted fast track designation to oral SETD2 inhibitor EZM0414 as an investigational agent for the treatment...

Therapeutic Heparin May Benefit Moderately Ill, Hospitalized Patients With COVID-19

The use of therapeutic heparin in hospitalized patients with moderately severe COVID-19 and increased D-dimer did not reduce the risk of a composite of...

Idiopathic Multicentric Castleman Disease: Identifying Prevalence and New Treatment Targets

Two recent studies published in Blood Advances explored idiopathic multicentric Castleman disease (iMCD). Researchers led by Sudipto Mukherjee, MD, MPH, of Cleveland Clinic, provided...

Long-Term Hydroxyurea May Improve Cardiac Abnormalities in Young Patients With Sickle Cell Disease

Long-term hydroxyurea therapy in children with sickle cell disease (SCD) may reverse cardiac remodeling, according to new research findings. Lead study author Arushi Dhar,...

Intravenously Administered CD19-Directed CAR T Cells Safe, Potentially Effective in Primary CNS Lymphoma

Intravenously administered CD19-directed chimeric antigen receptor (CAR) T-cell therapy was found to be safe and associated with high levels of complete remission (CR) in...
WIB_icon

How Safe Is Vaccination Against SARS-CoV-2 for Patients With De Novo and Preexisting ITP?

A report describing the effects of SARS-CoV-2 vaccination on platelet counts of patients with de novo and preexisting immune thrombocytopenia (ITP), including findings of...
WIB_icon

No Difference in CNS Relapse Rates Between IT and IV Prophylaxis Routes in Non-Hodgkin...

There was no significant difference in central nervous system (CNS) relapse rates between intrathecal (IT) or intravenous (IV) administration routes of prophylaxis administration for...
WIB_icon

BIOIRON Society Recommends New Classification of Hemochromatosis

During a meeting of clinicians and basic scientists in Heidelberg, Germany, a working group of the International Society for the Study of Iron in...
Advertisement

Current Issue

November 2021 Bonus ASH Annual Meeting Preview Edition

This issue offers a behind-the-scenes look at this year's annual meeting, and more.

Block title